An application claims non-naturally occurring upregulators of apolipoprotein A-I (ApoA-l) quinazolin-4(3H)-ones. The claimed quinazolin-4(3H)-ones are efficacious in upregulating the expression of endogeneous ApoA-l, and can potentially treat and prevent cardiovascular disease and related disease states, including cholesterol or lipid-related disorders, such as atherosclerosis. This application of Resverlogix Corp. increases the diversity of quinazolin-4(3H)-ones capable of upregulating the expression of endogeneous ApoA-l.